<DOC>
	<DOC>NCT00093314</DOC>
	<brief_summary>The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.</brief_summary>
	<brief_title>HuMax-CD20 in Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Chronic Lymphocytic Leukemia Circulating lymphocytes above a specific level Circulating lymphocytes showing certain markers Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment in study. Previous stem cell transplantation. Received any of the following treatments within 4 weeks prior to entering this trial: A) Anticancer therapy, B) Glucocorticoids unless less than 10 mg per day, C) Radiotherapy. HIV positivity. Hepatitis B or hepatitis C. Other cancerous diseases, except certain skin cancers and cervix cancer. Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases. Participation in another trial with a different new drug 4 weeks prior to enrollment in study. Current participation in any other clinical study. Pregnant or breastfeeding women. Women of childbearing age who are unable or unwilling to use adequate contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>B-cell Lymphoma</keyword>
</DOC>